ALMS
NASDAQ · Pharmaceuticals
Alumis Inc
$6.03
+0.18 (+3.08%)
Financial Highlights (FY 2026)
Revenue
36.63M
Net Income
-370,606,461
Gross Margin
—
Profit Margin
-1,011.8%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 62.0% | 62.0% | 62.0% |
| Operating Margin | -1,105.6% | 19.3% | 20.1% | 18.6% |
| Profit Margin | -1,011.8% | 13.7% | 18.2% | 15.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 36.63M | 878.33M | 917.39M | 923.52M |
| Gross Profit | — | 544.48M | 568.69M | 572.49M |
| Operating Income | -404,931,428 | 169.52M | 184.08M | 171.32M |
| Net Income | -370,606,461 | 120.27M | 166.79M | 141.53M |
| Gross Margin | — | 62.0% | 62.0% | 62.0% |
| Operating Margin | -1,105.6% | 19.3% | 20.1% | 18.6% |
| Profit Margin | -1,011.8% | 13.7% | 18.2% | 15.3% |
| Rev Growth | — | +6.0% | +16.1% | -7.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 414.28M | 427.86M | 516.43M |
| Total Equity | — | 1.64B | 1.41B | 1.63B |
| D/E Ratio | — | 0.25 | 0.30 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -399,668,556 | 272.46M | 241.94M | 249.41M |
| Free Cash Flow | — | 126.96M | 147.40M | 173.90M |